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Abstract The protein ARHGDIA has been found to play
distinct roles in cancer progression for several tumors.
However, it remains elusive whether and how ARHGDIA
plays functions in human glioma. In this study, we discovered
that ARHGDIA is much downregulated in human glioma;
meanwhile, its expression negatively correlates with glioma
malignancy and positively relates to prognosis of glioma pa-
tients. It has independent predictive value of ARHGDIA ex-
pression level for overall survival of human glioma patients.
Glioma patients with ARHGDIA-positive expression have a
longer overall survival time than ARHGDIA-negative pa-
tients. Knockdown of ARHGDIA promotes cell proliferation,
cell cycle progression, and cell migration due to the activation
of Rho GTPases (Rac1, Cdc42, and RhoA) and Akt phosphor-
ylation, whereas overexpression of ARHGDIA suppresses
cell growth, cell cycle progression, and cell migration.
ARHGDIA is a potential prognostic marker and therapeutic
target for human glioma.
Keywords ARHGDIA . Glioma . Downregulation . Rho
GTPase
Introduction
Glioma is the most common brain tumor, accounting for about
45 % of all brain tumors [1]. The World Health Organization
(WHO) classifies gliomas based on the different histolo-
gical tumor types (astrocytic, oligodendroglial, mixed
oligoastrocytic, and ependymal glioma), as well as malignan-
cy grades (I, II, III, and IV) [2]. The present treatment options
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the combination treatment of these methods, but the prognosis
of malignant glioma remains very poor. The median survival
is only 12 to 15months for patients with glioblastoma and 2 to
5 years for patients with anaplastic glioma in the USA [3]. So,
it is necessary to find biomarkers for early diagnosis and ef-
fective therapeutic targets to improve the prognosis for pa-
tients with human glioma [4].
The Rho GDP-dissociation inhibitors ARHGDIs (also
named RhoGDIs) are important regulators of the Rho fam-
ily of small GTPases which involves in cancer occurrence
[5]. ARHGDIs take part in several biological processes
during tumorigenesis and cancer progression. For example,
the expression of ARHGDIs is altered in a variety of can-
cers, including breast cancer [6] and hepatocellular carci-
noma [7]. Several novel therapeutic strategies are proposed
for intervening in ARHGDI signaling [8]. These reports
indicate that ARHGDI signaling may be targets for cancer
therapy.
ARHGDIA is one member of ARHGDIs, which is ubiq-
uitously expressed and interacts with several Rho
GTPases, mainly including RhoA, Rac1, and Cdc42 [9].
As a regulator of Rho GTPase activity, ARHGDIA has
attracted increasing attentions. Previous studies have indi-
cated the aberrant expression of ARHGDIA is associated
with cancers [6, 7], whereas there is no research in detail
on glioma. So our investigation aim is to explore
ARHGDIA functions in glioma development. Our analyses
reveal that ARHGDIA is frequently downregulated in hu-
man glioma tissues and it is significantly associated with
tumor malignancy degree.
Materials and methods
Glioma patients and tissue samples
This study was approved by the Institutional Ethics
Committee of State Key Laboratory of Biotherapy, West
China Hospital of Sichuan University. A total of 73 glioma
patients were enrolled in our study. The clinical information of
patients was summarized in Table 2. The patients did not
receive any preoperative cancer treatment, and their follow-
up data were available. They were followed-up since the sur-
gical treatment until May 2015, with a median follow-up of
20.4 months (range 0.2–68 months). During the follow-up,
patients were monitored every 2–3 months by clinic interview
or phone call.
Seventy-three pairs of human glioma tissues (HGTs) and
patients’ autologous para-cancerous brain tissues (PBTs) were
surgically resected to collect with patient’s informed consent
in West China Hospital, Sichuan University (Chengdu, P. R.
China).
Immunohistochemical analysis
The tissues paraformaldehyde-fixed and paraffin-embedded
were cut into sections of 5 μm thickness for hematoxylin-
eosin (HE) and immunohistochemistry (IHC) analysis mainly
according to our previous protocols [10]. The anti-ARHGDIA
antibody (Santa Cruz Biotechnology, 1:100) was used to de-
tect the protein expression in human glioma and non-cancer
tissues. Finally, the tissue slices were visualized by the 3,3-
diaminobenzidine solution and nuclei were slightly counter-
stained with hematoxylin. Substitution of the primary anti-
body with phosphate-buffered saline was served as a control
for IHC. The intensity and percentage of positive cells were
evaluated in at least five separate fields at ×400magnification.
The staining intensity was scored as 0 (negative), 1 (weak),
2 (moderate), or 3 (strong). The extent of staining was scored
based on the percentage of positive tumor cells: 0 (negative), 1
(1–25 %), 2 (26–50 %), 3 (51–75 %), and 4 (76–100 %) [11,
12]. The final score of each sample was assessed by summa-
rization of the results of the intensity and extent of staining.
Therefore, each case was considered negative if the final score
was 0 (−) and positive if the final score was 1–2(weak, +),
more than 2 (strong, ++), respectively. The scoring was deter-
mined independently by two senior pathologists.
Association analysis of ARHGDIA expression with glioma
clinical information
The relationship between ARHGDIA expressions with glioma
clinical information was assessed based on IHC data of glioma
tissues using Pearson’s χ2 test. The clinical information included
glioma patient’s gender, age, tumor grades (seen in the Table 2),
and patient prognosis. Among 73 glioma patients, only 37 pa-
tients whose follow-up time was more than 5 years, and the
follow-up time of other 36 glioma patients was less than 5 years
but all more than 3 years. The patient overall survival (OS) was
evaluated using the Kaplan-Meier method. The 73 glioma pa-
tients were grouped into two groups based on the protein ex-
pression level, including ARHGDIA-negative expression
(n= 32) andARHGDIA-positive expression (n= 41). The group
differences were assessed using the log-rank test.
Cell culture
Human glioma cell lines H4 and U87 were ordered from
American Type Culture Collection (Manassas, VA), and
U251 were ordered from the Type Culture Collection of the
Chinese Academy of Sciences (Shanghai, China). Cells were
cultured in DMEM medium containing 10 % fetal bovine
serum (FBS) (16000-044, Gibco), with 100 U/ml penicillin
and 100μg/ml streptomycin. Cells were incubated in 37 °C
with 5 % CO2 and 95 % air.
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ARHGDIA-specific siRNAs, expression plasmid, and cell
transfection
In order to reduce the off-target effects of single siRNA, three
different siRNAs against ARHGDIA had been designed and
synthesized to perform the ARHGDIA knockdown experi-
ments. One of siRNAs, siRNA1 against ARHGDIA, was syn-
thesized based on one previous reported paper [13]. The other
two siRNAs, siRNA2 and siRNA3, were designed according
to our bioinformatics analysis and synthesized by the RiboBio
company (RiboBio, Guangzhou, China). ARHGDIA-specific
siRNA1 sequences were designed as follows: 5 ′-
UCAAUCUUGACGCCUUUCC-3′. The siRNA2 and
siRNA3 sequences were respectively designed as following:
(siRNA2) 5 ′-GAGCACTCGGTCAACTACA-3’and
(siRNA3) 5′-GGTGTGGAGTACCGGATAA-3′. The non-
targeting control siRNA oligonucleotides were 5′-UUC
UCC GAA CGU GUC ACG U-3.
In order to observe cell growth and Akt signaling under
ARHGDIA knockdown, 100 nM ARHGDIA-specific
siRNA was respectively transiently transfected into glioma
cells for one well of a 6-well plate for 48 h culture using the
INTERFERin transfection reagent (Polyplus Transfection).
The ARHGDIA cDNA (gi 669033301) was cloned into the
expression vector pcDNA3.1-HA to obtain the recombinant
plasmid pHA-ARHGDIA. The overexpression of ARHGDIA
by transfection of pHA-ARHGDIA plasmids into U87 cells
was performed to detect its effects on cell growth and migra-
tion. Two-microgram plasmids were transfected for each well
of a 6-well plate with the reagent Lipofectamine 2000 (Cat.
11668-019, Life Technologies).
Quantitative RT-PCR
To compare endogenous gene expression in HGTs versus
PBTs, RNA samples were prepared fromHGTs or PBTs using
TRIZOL reagent (Cat. #15596-026, Invitrogen). First-strand
complementary DNA (cDNA) synthesis was carried out with
the cDNA synthesis kit (Cat. #170-8891, Bio-Rad). PCR re-
action was carried out with first-strand cDNA and one set of
specific primers. For each primer set, two or three cycle num-
bers were tested to confirm that PCR product accumulates
within a linear range. The GAPDH was amplified as a control
marker with specific primers. The relative RNA expression
was calculated with the comparative CT method, which was
normalized to the internal references. The RT-PCR primers for
ARHGDIA were designed as follows: forward primer 5′-
CCTCACACTGCCCCAGAGGAT-3′ and reverse primer 5′-
GCGCACTTCTGAGCAGGAGT-3′ [14]. The forward prim-
er 5′- TGG AAG GAC TCA TGA CCA CA-3′ and reverse
primer 5′- TTC AGC TCA GGG ATG ACC TT-3′ for the
control GAPDH.
Western blot
Cell pellets were harvested after being transfected with
ARHGDIA-specific siRNAs or the pHA-ARHGDIA plas-
mids for 48 h. Cells were lysed to extract proteins with
RIPA buffer (50 mM Tris base,1.0 mM EDTA, 150 mM
NaCl, 0.1 % SDS, 1 % Triton X-100, 1 % sodium
deoxycholate, and 1 mM PMSF). Proteins were separated
on 12 % SDS-PAGE, transferred to polyvinylidene
difluoride (PVDF) membrane to incubate with rabbit anti-
ARHGDIA antibody (1:100, Santa Cruz Biotechnology) at
4 °C overnight. A secondary antibody incubation was per-
formed with horseradish peroxidase (HRP)-tagged anti-
goat (Santa Cruz) or HRP tagged anti-rabbit (Invitrogen)
antibody. The PVDF membrane was re-probed with mouse
anti-GAPDH antibody (Abcam) for normalization of sig-
nal. Detection was performed with Western blot reagent
ECL (Amersham Biosciences).
Pull-down analysis of active Cdc42/Rac1 and RhoA
The pull-down procedures were performed based on the
commercial antibody against the active form of Cdc42,
Rac1, and RhoA (MuCyte Biotechnology, Nanjing,
China). Cell pellets from U87 cells transfected with
ARHGDIA-specific siRNA1 or pHA-ARHGDIA plasmids
for 48 h were collected and resolved in 1 ml of ice-cold
1 × assay/lysis buffer for 10 min. Protein supernatant was
obtained by centrifugation with 14,000×g for 10 min at
4 °C. Fifty microliters slurry of glutathione resin was
washed with 1 × assay/lysis buffer, and 60 μl of GST-
RBD (Rho-binding domain ) or 20 μl GST-PBD(p21-bind-
ing domain) was added to bind with the resin on ice for
pull-down active RhoA, Rac1, or Cdc42, respectively.
Then 1 mL protein solution was added to incubate with
the antibody-combined resin at 4 °C for 1 h with gentle
agitation. The supernatant was removed by 7200×g centri-
fugation for 1 min, and the resin was washed three times
with 0.5 ml of 1 × assay/lysis buffer, suspended in 30 μl of
2× reducing SDS-PAGE sample buffer to pull down the
target proteins by boiling for 5 min. The sample was sep-
arated on 12 % SDS-PAGE to detect the target proteins by
Western blot. The first antibodies included rabbit monoclo-
nal antibody against RhoA (1:1000, Sion Biological),
mouse monoclonal antibody against Cdc42 (1:1000,
Abcam), and mouse monoclonal against Rac1 (1:1000;
Abcam).
Cell proliferation
Cell proliferation was measured using the Cell Counting Kit-8
(CCK-8) assay (cat.ZP328-3, ZOMANIO). Three thousand
cells were plated into each well of a 96-well plate after
Tumor Biol. (2016) 37:15783–15793 15785
transfection with pHA-ARHGDIA plasmids or ARHGDIA-
specific siRNA1 for 48 h, in which 10 μl CCK-8 reagents was
added to 90 μl of culture medium. Cells were subsequently
incubated for 2 h at 37 °C and the absorbance was measured at
450 nm on Multiskan MK3 (Thermo Scientific). Three inde-
pendent experiments were performed.
Flow cytometry
For cell cycle analysis, cells were harvested after siRNA1
treatment for 48 h, fixed in 70 % ethanol on ice and stained
with propidium iodide in phosphate-buffered saline contain-
ing RNase for 15 min at 37 °C in the dark. The DNA contents
Fig. 1 ARHGDIA is
downregulated in human glioma.
A ARHGDIA is detected in three
randomly chosen HGTs via real-
time PCR and western blot
analysis. The transcript levels
were normalized to GAPDH.
Data are presented as the mean
and standard deviation (SD) of
three independent experiments. B
Immunohistochemical staining of
ARHGDIA in HGTs and PBTs.
Tissue hematoxylin-eosin
staining (a–d); ARHGDIA-
negative (e) and ARHGDIA-
positive expression ( f ) in HGTs,
ARHGDIA-negative (g) and
ARHGDIA-positive expression
(h) in PBTs. C ARHGDIA
expression in different
histological glioma tissues. PA:
pilocytic astrocytoma, DA:
diffuse astrocytoma, AA: anaplastic
astrocytoma, GBM: glioblastoma.
Scale bar represents 50 μm
(original magnification × 400).
HGTs: human glioma tissues;
PBTs: para-cancerous brain tissues.
***means p < 0.01, ****means
p < 0.001
Table 1 ARHGDIA immunoreactivity between HGTs and PBTs
Immuno -reactivity HGTs (n = 73) PBTs (n = 13) p value
Percentage Score Percentage Score
Negative 34.2 %(25/73) 0 (−) 15.4 %(2/13) 0 (−)
Positive 65.8 %(48/73) 1.396 ± 0.08 (+) 84.6 %(11/13) 2.375 ± 0.42 (++) p < 0.05
P value was calculated the difference between ARHGDIA-positive HGTs and PBTs using Student’s t test. P < 0.05 was considered statistically
significant
HGTs: human glioma tissues, PBTs: para-cancerous brain tissues
−: negative; +: weak expression; ++: strong expression
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were analyzed by flow cytometry (NovoCyte, ACEA
Biosciences).
In vitro migration assays
Cell migration was performed using our previous method
[11]. The 1 × 104 cells were added into the upper chamber
of the insert with the non-coated membrane (Millipore, 8-mm
pore size). Cells were plated in serum-free medium, and me-
dium containing 10 % FBS in the lower chamber served as
chemo-attractant. After 24 h of incubation, cells that did not
migrate through pores were carefully wiped out with cotton
swab. Cells on the lower surface of the membrane were fixed
with methanol and stained with Giemsa (cat. C0121,
Beyotime). Images were captured using an inverted micro-
scope (Olympus), and the migrated cells were counted manu-
ally. Each experiment was performed in triplicates.
Statistical analysis
Statistical analysis was performed and values were
expressed as the mean ± standard deviation. The differ-
ences between groups were analyzed using Student’s t test
(only two groups) or one-way analysis of variance (more
than two groups were compared). P < 0.05 was considered
statistically significant.
Results
ARHGDIA downregulation in glioma tissues
The low expression status of ARHGDIA at mRNA and pro-
tein levels was detected in HGTs. Compared with the expres-
sion level in PBTs, ARHGDIAwas greatly decreased in glio-
ma tissues both at mRNA and protein levels (Fig. 1A).
Moreover, the decreased expression of ARHGDIA was
validated in 73 cases of HGTs compared with 13 PBTs by
IHC (Table 1). As results, more than one thirds of human
glioma tissues (n = 25, 34.2 %) had ARHGDIA-negative ex-
pression, and other 48 cases (65.8 %, 48/73) showed weak
expression of ARHGDIA in cytoplasm (Fig. 1B-f ), with
mean staining scores 1.396 ± 0.08. While in 84.6 % (11/13)
PBTs, ARHGDIAwas detected with a higher expression level
with an average staining score 2.375 ± 0.42 (Fig. 1B-h).
Generally, a lower expression of ARHGDIAwidely exists in
gliomas than that in noncancerous brain tissues (p < 0.05).
ARHGDIA downregulation correlates with tumor stage
and patient survival
In order to evaluate whether ARHGDIA is a potential diagno-
sis or prognosis factor in clinical test, we analyzed the rela-
tionship between the expression of ARHGDIA and the clini-
copathologic features of human glioma patients. The expres-
sion levels of ARHGDIA in glioma exhibit a tumor
Table 2 Associations of
ARHGDIA expression with the




ARHGDIA expression Average score Expression level p value
Negative (n = 24) Positive (n = 49)
Gender
Male 9 30 1.42 ± 0.10 + 0.081
Female 15 19 1.35 ± 0.15 +
Age, (years)
≤56 10 31 1.46 ± 0.11 + 0.131
>56 14 18 1.28 ± 0.11 +
TNM stage
I–II 11 9 1.67 ± 0.23 + 0.048
III–IV 12 33 1.27 ± 0.08 +
Unknown 1 7
+: ARHGDIA staining was scored 1–2 (weak expression)
Fig. 2 Association of ARHGDIA expression and overall survival of
glioma patients. The overall survival has highly significant differences
between ARHGDIA-positive patients (n = 41) and ARHGIDA-negative
expresses (n = 32) (p < 0.05 by the log-rank test). The 1-, 3-, and 5-year
OS rates of the patients with low level were 39.8, 30.1, and 26.7 %,
respectively, which were significantly lower than those with high level
group (78.6, 52.4, and 44.8 %, respectively; p = 0.005). Patients with low
level of ARHGDIA have a worse postoperative overall survival
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pathological grade-dependent pattern (Table 2, p = 0.048).
And a significantly relative stronger ARHGDIA exists in high
differentiated glioma (TNM stage I and II) than in low differ-
entiation tumors (TNM stage III and IV) (Table 2). Moreover,
ARHGDIA expression differs in different histological glio-
mas, including pilocytic astrocytoma, diffuse astrocytoma, an-
aplastic astrocytoma, and glioblastoma (Fig. 1C). But the
expression level of this protein has no relationship with pa-
tient’s gender and age (Table 2).
Furthermore, to determine the relationship between protein
expression and OS of patients, 73 glioma patients were grouped
into two groups, including ARHGDIA negative (n = 32) and
positive (n = 41) expression. The ARHGDIA expression level is
associated with prognosis of 74 glioma patients whose follow-
Fig. 3 ARHGDIA
downregulation promotes cell
proliferation in vitro. a
ARHGDIA expression in
different human glioma cell lines.
b–d The interference effect of
three siRNAs in H4, U251, and
U87 cells. e–f ARHGDIA
knockdown in H4 (e) or U251
cells (f) by siRNA1 treatment for
48 h promotes cell proliferation
by decreasing proportion of G2/
M-phase cells (*p < 0.05).
siControl: nontargeting control
siRNA. g The overexpression of
ARHGDIA in U87 cells with
transfection of pHA-ARHGDIA
plasmids for 48 h inhibits cell
proliferation by increasing the
proportion of G2/M-phase cells
(*p < 0.05)
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up timemore than 3 years. The Kaplan–Meier estimates showed
significant differences in OS rates between ARHGDIA-negative
patients and those with ARHGDIA-positive expression
(P = 0.005 by the log-rank test; Fig. 2). The 32 patients with
ARHGDIA-negative expression had a worse postoperative OS
compared to the 41 cases of ARHGDIA-positive group
(p = 0.005). The median survival in 41 ARHGDIA-positive
patients was 25.0 months, whereas the median survival of
ARHGDIA-negative patients was just 11.0months. On the other
hand, the 1-, 3-, and 5-year OS rate of the patients with the
protein negative expression was 39.8, 30.1, and 26.7 %, respec-
tively.Whereas the 1-, 3-, and 5-year OS rate of patients with the
protein positive expression was 78.6, 52.4, and 44.8 %, respec-
tively. All these data mean that patients with ARHGDIA-
positive expression have a longer overall survival. Generally,
ARHGDIA expression level is associated with tumor grade,
survival, and prognosis of glioma patients.
ARHGDIA expression regulates cell proliferation and cell
cycle
We detected the endogenous expression level of ARHGDIA
in three different malignant glioma cell lines, including H4,
U251 and U87 cells. The expression level of ARHGDIA in
H4 and U251 has no obvious difference, but this protein is
expressed in a relatively low level in U87 cells (Fig. 3a). We
further explored this protein effects on cell growth and cell
biological process by ARHGDIA knockdown in H4 cell,
U251 cells and ARHGDIA overexpression in U87 cells.
The three different siRNAs had obvious interference ef-
fects for the target gene ARHGDIA expression in H4, U251,
and U87 cells (Fig. 3b–d). The siRNA1 against ARHGDIA
had the most effective inhibition for the protein. The inhibito-
ry efficiency of 100 nM specific siRNA1 was up to 90 % at
protein expression in these glioma cells. So we further mea-
sured cell growth responsive to siRNA1 treatment.
ARHGDIA knockdown with siRNA1 significantly improved
cell proliferation rate by decreasing cell proportion of G2/M-
phase in H4 and U251 cells (Fig. 3e, f).
On the contrary, when the ARHGDIA protein is
overexpressed to two times after being transfected with
pHA-ARHGDIA plasmids in U87 cells, cell proliferation rate
obviously decreased by increasing the proportion of G2/M-
phase cells (Fig. 3g). The results suggest that ARHGDIA
downregulation promotes glioma cell proliferation by regulat-
ing cell cycle distribution.
Fig. 4 ARHGDIA knockdown
promotes cell migration in H4 and
U251 cells (a–b). While
ARHGDIA overexpression in
U87 cells inhibits cell migration
(c). NC: nontargeting control
siRNA or pHA empty vector.
*p < 0.05
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ARHGDIA downregulation promotes glioma cell
migration
Next, cell migration was further analyzed to know if
ARHGDIA has a crucial role in glioma cell migration ability.
When ARHGDIA was knockdown by siRNA1 in H4 and
U251 cells, the average number of migrated cells was signif-
icantly increased to near twofold in comparison with those by
nonspecfic siRNA treatment (P < 0.05, Fig. 4a, b). This indi-
cated that the migration potential of human glioma cells was
markedly promoted after knockdown of ARHGDIA.
Conversely, ARHGDIA overexpression in U87 cells resulted
in low ability of cell migration (Fig. 4c).
In conclusion, the ARHGDIA downregulation may be an
important contributor to cell migration, and the expression
level of ARHGDIA affects the metastatic behavior of human
glioma cell lines.
Downregulation of ARHGDIA increases activity of Rho
GTPases
ARHGDIs regulate the cytosol-membrane cycling of the Rho
GTPase, which has a major role in controlling Rho GTPase
activity and function [5]. Due to the important role of
ARHGDIA in the regulation of Rho GTPase, then how does
its decreased expression regulate its effector proteins includ-
ing Rac1/cdc42 and RhoA in glioma cells? Based on the
above conclusion of lower ARHGDIA contribution to cell
growth and cell migration, we conducted pull-down assays
to determine the GTP status of Rac1/cdc42 and RhoA in U87
cells after being transfected with siRNA1 and pHA-
ARHGDIA plasmids in triplicates. As expected, the lower
expression of ARHGDIA significantly induced the activation
of Rac1, Cdc42, and RhoA with GTP status in U87 cells
treated with ARHGDIA siRNA1 (Fig. 5a). In response to
ARHGDIA knockdown, the GTPase activity of Cdc42 and
RhoA was averagely increased to 2.63- and 5.50-folds, re-
spectively, and the Rac1 was also elevated to nearly twofolds
(Fig. 5b). But the higher expression of ARHGDIA signifi-
cantly suppressed the active state of Rac1, Cdc42, and RhoA
with GTP status in U87 cells (Fig. 5c). Responsive to influ-
ence of ARHGDIA overexpression, the GTPase activity of
Cdc42 and Rac1 was averagely decreased to 1.89- and 1.92-
folds, and the GTPase activity of RhoA almost had almost no
detection level (with average 6.8-folds decrease)(Fig. 5d). So
we concluded that it has a significant role in the Rho GTPase
signaling pathway by perturbations of ARHGDIA.
Combined with the above conclusion of ARHGDIA down-
regulation in glioma cell migration, our studies confirmed
that activation of signaling of Rho GTPases induced by si-
lencing ARHGDIA contributes to cancer progression and
metastasis for glioma.
Downregulation of ARHGDIA increases Akt
phosphorylation
It had indicated that the GTPases of the Rho family control
somemajor components of cellular signal transduction includ-
ing Akt signaling, and inhibition of these GTPases leads to a
decrease in Akt activity [15]. In this study, we also found that
the phosphorylation of Akt (p-Akt) was high in human glioma
cell lines, and the more higher degree of malignancy, the ex-
pression level of p-Akt was more higher (Fig. 6a). At the same
time, we determined the expression level of p-Akt in HGTs
and PBTs, the p-Akt expression was significantly increased in
HGTs than PBTs (Fig. 6b). Combined with the ARHGDIA
expression in HGTs, the above results suggest that the p-Akt
expression may play an important role in the human glioma.
In order to explore whether the ARHGDIA expression had
effects on p-Akt level, the phosphorylation level of Akt was
Fig. 5 ARHGDIA knockdown (a) or overexpression (c) affects the
GTPase activity of Rho family proteins. Rac1, Cdc42, and RhoA with
GTP form represents the GTPase activity, which was analyzed from cell
lysis after enrichment by pull-down. Total target proteins (Rac1, Cdc42,
and RhoA) were present in whole cell lysate. The integrated density
measurements were calculated based on the fold change of active-form
protein versus total target protein. The gray value of control treatment
(NC) was set as 1. The immunoblot quantitation of GTPase activity was
shown in (b) and (d). NC nontargeting control siRNA or pHA empty
vector. *p < 0.05, **p < 0.01
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further examined by Western blot after overexpression or
knockdown of ARHGDIA in U87 cells. In order to reduce
the off-target effects of single siRNA, we measured Akt phos-
phorylation changes responsive to ARHGDIA knockdown
with three siRNAs (siRNA1, siRNA2, and siRNA3) treat-
ment. The Akt phosphorylation was respectively upregulated
to 1.63-, 1.78-, and 2.34-folds in U87 cells by the siRNA1,
siRNA2, and siRNA3 incubation for 48 h compared with the
nontargeting siRNA treatment ( Fig. 6c). On the contrary, Akt
phosphorylation was decreased to 2.27-folds in ARHGDIA-
overexpressing U87 cells (Fig. 6d). Therefore, the downregu-
lation of ARHGDIA regulates GTPase activity of Cdc42,
Rac1, and RhoA, subsequently, increases Akt phosphoryla-
tion and leads to glioma cell proliferation and migration.
Discussion
Numerous studies indicate that GTPase signaling pathway
closely correlates with tumors [16], and the expression of
RhoGDIs which are the regulators of the Rho family of small
GTPases is altered in different cancers. For instance,
ARHGDIA expression is upregulated in colorectal [17] and
ovarian cancers [18]. However, a significant reduction of
Fig. 6 The Akt phosporylation
level in human glioma cell lines
(a, c) and in 3 randomly chosen
HGTs (b, d). The 3 randomly
chosen HGTs were the same
samples used in the Fig. 1. The
Akt phosporylation level was
correlative with ARHGDIA
expression in U87 cells and
HGTs. siControl and pHA-
control were the nontargeting




was the phosphorylated AKT
Fig. 7 Schematic diagram summary of ARHGDIA effects on tumor
progression in human gliomas. Under normal physiological conditions,
ARHGDIA inhibits activation of Rho proteins by maintaining the GDP-
bound Rho proteins in cytosol (a). When ARHGDIA protein is
downregulated in glioma, the GTP-form Rho GTPases are activated (b)
and subsequently Akt phosphorylaton is elevated, which promotes cell
proliferation, cell cycle, and cell migration
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ARHGDIA expression is detected in breast cancer [6]. In ad-
dition, ARHGDIA downregulation is associated with poor
prognosis in hepatocellular carcinoma [7]. These different ex-
pression profiling even opposite results on this protein in sev-
eral cancers urgently drives us to know how ARHGDIA me-
diates the processes during tumorigenesis and cancer progres-
sion in human glioma.
It has been reported ARHGDIA interacts with different
proteins to involve in cell motility. ARHGDIA can interact
with αvβ8 integrin, and ARHGDIA-αvβ8 integrin protein
complexes recruit GDP-bound Rac1 and Cdc42 to control
activation of Rho proteins. When silencing ARHGDIA gene
expression leads to elevated levels of GTP-bound Rho pro-
teins, which results in diminishing cell polarity and invasion
[19]. Moreover, phosphorylation of ARHGDIA on Y156
leads to deposition of Rac1/Cdc42 proteins and enabling their
activation to promote directional cell motility [20]. These in-
dicate that the ARHGDIA protein affects the activation of Rho
proteins mainly via coupling other proteins such as αvβ8
integrin. On the other hand, although ARHGDIA has been
reported to decrease in brain tumors before [21], but there
could not clearly clarify which member of RhoGDI family
to change and its specific biological effects. In the present
study, we further investigated the role of ARHGDIA in human
glioma, and we firstly discovered the relationship between the
dysregulation of ARHGDIA and glioma progression. Our re-
search showed that ARHGDIA is frequently down-regulated
in human glioma and significantly correlates with prognosis
of glioma patients.
As the regulator of Rho GTPases family, we further focus
on the changes of Rho GTPase proteins after ARHGDIA
knockdown in human glioma cells. Previous researches had
indicated that downregulation of ARHGDIA had a different
effect on the activation of Rho GTPase family members in
different tumor types. For example, Turner et al. found that
the member of RhoGTPase was increased significantly in the
HeLa cells transfected with ARHGDIA siRNA [22]. In myo-
cardial cells, overexpression of ARHGDIA significantly in-
hibits the activities of Rac1, Cdc42, and RhoA [23]. But in
ARHGDIA-knockout mice, renal abnormality is just associ-
ated with an increase of Rac1 but not RhoA [24], whereas loss
of ARHGDIA significantly induced the activation of Rac1,
RhoA but not Cdc42 in HCC [7]. By now, we found that
knockdown of ARHGDIA by siRNA resulted in activating
the GTPase activity of Cdc42, Rac1, RhoA, and pAkt to pro-
mote glioma cell proliferation and migration. To the best of
our knowledge, this is the first study to discover the downreg-
ulation of ARHGDIAwith glioma tumor progression by mul-
tiple biochemical analyses, overexpression, and knockdown
in vitro combined with clinical sample validation.
Akt acts downstream of Rac1 and Cdc42 in the control of
cellular survival [15], which indicates that Akt signaling is
closely related to Rho GTPase signaling pathway. And our
data supported that the activation of GTPase activity increases
the downstream phosphorylated Akt signaling, which finally
induces cell proliferation and cell cycle progression in human
glioma cells. So based on the results of our research and liter-
ature reported, the potential action mechanism of ARHGDIA
in glioma is summarized as following (Fig. 7). Under cell
normal physiological conditions, ARHGDIA level makes a
balance state of the GDP-bound inactive form and GTP-
bound GTPase form of Rho family proteins (Fig. 7a). While
the low expression of ARHGDIA in human glioma attenuates
the inhibition effects of the GDP-bound inactive Rho family
protein, and the GTP-bound form of Rho GTPases (Cdc42,
Rac1, and Rho) is activated to switch on downstream path-
ways by acting on theirs effectors including improving phos-
phorylated Akt (Fig. 7b), which finally promotes cancer bio-
logical process including cell proliferation, cell cycle progres-
sion, and cell migration.
ARHGDIA, Rho GDP-dissociation inhibitor 1; HGTs: hu-
man glioma tissues; IHC, immunohistochemistry; PBTs, para-
cancerous brain tissues; siRNA, small interfering RNA
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